Last updated: 2026-09-16 10:32:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Caribou Biosciences, Inc. (CRBU) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1,29, with a market capitalisation of $138,30M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,25 to $3,54. This page covers its latest market performance, valuation, price trends and company information.
$138,30M | |
$1,29 | |
$32,65 | |
$0,66 | |
$1,27 | |
816,00 | |
1,67M | |
-- | |
$3,54 | |
$1,25 | |
-- | |
-- |
Caribou Biosciences, Inc. (CRBU) is trading at $1,29 in pre-market trading as of 2026-09-16 10:21:00, up 1,57% ($0,02) from the previous close of $1,27
Pre-market trading shows how investors are pricing CRBU before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Caribou Biosciences, Inc. (CRBU) moved from $1,57 to $1,29, representing a decline of 17,83% ($0,28).
The stock traded between $1,25 and $1,60 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,56 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1,8%
CRBU is currently trading at $1,29, placing it 1,8% of the way from its 52-week low of $1,25 to its 52-week high of $3,54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 97 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Caribou Biosciences, Inc. (CRBU) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.